Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brian Pereira resigns from AMAG

This article was originally published in Scrip

Executive Summary

In the same week that AMAG Pharmaceuticals' proposed acquisition of Allos Therapeutics fell through costing the company approximately $1.9 million in the third quarter, and $2 million to be recognised in the fourth quarter, Dr Brian Pereira, AMAG's president and CEO, has resigned. He has also resigned from the board of directors but will remain a strategic advisor to the company on some matters, including the ongoing development and regulatory work on its Phase III programme for iron deficiency anaemia. Gary Zieziula, AMAG's chief commercial officer has also left the company. Frank Thomas, the company's CFO, has been promoted to COO and appointed interim president and CEO. AMAG has launched a search for a permanent replacement for Dr Pereira. Additionally, AMAG's board has established a special committee consisting of Michael Narachi, Robert Perez and Dr Lesley Russell to oversee the transition period.

You may also be interested in...



Almirall launches Constella in six European markets

Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.

Dermira raises $35m in series B

Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.

Clovis ups public offering to $240m

Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.

Topics

Related Companies

UsernamePublicRestriction

Register

SC015122

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel